Does tirzepatide come in different strengths — and how do you decide which one is right?

Why the decision isn't really 'which strength', it's 'how far, and how fast'

The six doses of Mounjaro aren't separate options you choose between like sizes in a shop. They form a single, structured ladder that every patient climbs in sequence. The question your prescriber is really helping you answer is: how far up that ladder should you go, and how quickly can your body tolerate each step?

The 2.5 mg pen is the starting point for everyone. It exists because tirzepatide (as a dual GIP and GLP-1 receptor agonist) slows gastric emptying and suppresses appetite quite effectively, and the body needs a settling-in period to manage those effects without significant nausea. Think of that first four weeks less as treatment and more as preparation. Most people then move to 5 mg, then 7.5 mg, and so on, roughly monthly, though the pace is always led by clinical judgement rather than a fixed calendar.

Not everyone reaches 15 mg. Some people find that 10 mg or 12.5 mg achieves the progress they need with a side-effect profile they can comfortably live with. Pushing higher for its own sake isn't the goal. The aim is the lowest dose that works well for you, a judgement that belongs with a prescriber who knows your full picture, not a general rule that applies to everyone. If you'd like to read more about the clinical detail behind each step, our page covering the full range of Mounjaro strengths covers the dose-by-dose specifics.

What the evidence says about higher strengths of tirzepatide

The SURMOUNT-1 trial (a large randomised study published in the New England Journal of Medicine) followed adults with obesity over 72 weeks. At the 15 mg dose, participants lost around 20–21% of their body weight on average, with some analyses reporting results approaching 22.5%. Lower doses produced meaningfully lower averages. The data make clear that each step up the dose ladder generally adds benefit, which is why clinical guidance supports titrating to the highest well-tolerated dose rather than staying at a comfortable middle ground indefinitely.

NICE's appraisal of tirzepatide (TA1026) recommends continuing treatment only if clinically meaningful progress is achieved; if less than 5% weight loss occurs after six months at the highest tolerated dose, the prescriber reviews whether continuing is appropriate. That built-in checkpoint matters: the strengths aren't just rungs to climb, they are also decision points at which your clinical team reassesses value and fit.

It's also worth being clear about what the trial figures represent. These are averages across thousands of participants. Individual results vary, some people respond more strongly at moderate doses, others need the full 15 mg to see the effect they're hoping for. A prescriber who understands your health context is better placed than any headline figure to predict where you might land on that range. If you're curious about what the different doses of Mounjaro actually are, our dedicated page walks through each available option in detail.

Practical things that change as the strength increases, and what to expect

Each dose increase brings renewed gastrointestinal adjustment. Nausea, loose stools or reduced appetite tend to be most noticeable in the first week or two after moving up, then settle for most people. That pattern repeats at each new step, which is part of why the monthly cadence exists, it gives the body time to adapt before adding another increment.

The pen itself stays the same format throughout: a pre-filled KwikPen with four doses inside, injected once weekly into the abdomen, thigh or upper arm on a rotating basis. You keep the pen in the fridge until you need it. When treatment is dispatched through our pharmacy, it travels by DPD overnight in plain, unbranded packaging with a tracking link, cold-chain integrity maintained throughout. The pen you open looks the same whether it contains 2.5 mg or 15 mg; the difference is the dose cartridge inside.

Storage follows the same rules regardless of strength: refrigerated between 2–8°C, with a limited window at room temperature before use. The exact room-temperature allowance is specified in the Patient Information Leaflet that comes with your pen, that's the definitive source, and worth reading before you travel. For the formal prescribing detail, the Mounjaro SmPC on the eMC covers storage and handling comprehensively.

Side effects are broadly consistent across doses (the GI profile described above) but intensity can increase with dose for some people. Reporting anything unexpected to your prescriber promptly lets them decide whether to slow the titration, hold the current dose for longer, or adjust the plan. That ongoing relationship is where dose decisions really live. If you're weighing up how the different doses of Mounjaro compare on cost and effect, our treatment page shows current pricing transparently.